Update on Blood-based Biomarkers for Chronic Liver Diseases Prognosis: Literature Review and Institutional Experience

Overview

Journal JGH Open

Specialty Gastroenterology

Date 2021 Nov 24

PMID 34816010

Citations 5

Authors

Motoh Iwasa

Ryuta Shigefuku

Akiko Eguchi

Yasuyuki Tamai

Yoshiyuki Takei

Affiliations

Soon will be listed here.

Abstract

Liver cirrhosis is the final stage of chronic liver disease (CLD) and is associated with high morbidity and mortality. Various complications such as portal hypertension, ascites retention, hepatic encephalopathy, and hepatorenal syndrome deeply affect patient outcome. The most common tools to predict the outcome of a CLD patient include the following: assessing severity of portal hypertension; scoring systems such as the model of end-stage liver disease and Child-Pugh score and blood biomarkers related to complications and/or survival rate. In this article, we summarize recent studies of noninvasive markers for predicting impending complications related to CLD and discuss the clinical value of currently available blood biomarkers based on evidence from the literature. In addition, noninvasive blood biomarker assays for different prognostic functions were validated on 113 liver cirrhosis patients at our institution using Kaplan-Meier curve analysis to confirm that these markers can satisfactorily predict CLD-related patient death.

Citing Articles

Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases.

Durazzo M, Ferro A, Navarro-Tableros V, Gaido A, Fornengo P, Altruda F Biomolecules. 2025; 15(1).

PMID: 39858515 PMC: 11763965. DOI: 10.3390/biom15010121.

The correlation of ADMA with proinflammatory, liver injury and cancer biomarkers in patients with liver dysfunction.

Lembas A, Mikula T, Sapula M, Barczak S, Badura B, Wiercinska Drapalo A Hepatol Forum. 2024; 5(4):171-177.

PMID: 39355835 PMC: 11440223. DOI: 10.14744/hf.2023.2023.0068.

Interpretations of the Role of Plasma Albumin in Prognostic Indices: A Literature Review.

Gradel K J Clin Med. 2023; 12(19).

PMID: 37834777 PMC: 10573484. DOI: 10.3390/jcm12196132.

The 3Rs in Experimental Liver Disease.

Martinez-Lopez S, Angel-Gomis E, Sanchez-Ardid E, Pastor-Campos A, Pico J, Gomez-Hurtado I Animals (Basel). 2023; 13(14).

PMID: 37508134 PMC: 10376896. DOI: 10.3390/ani13142357.

Elevation of enterococcus-specific antibodies associated with bacterial translocation is predictive of survival rate in chronic liver disease.

Iwasa M, Eguchi A, Tamai Y, Shigefuku R, Nakagawa R, Hasegawa H Front Med (Lausanne). 2022; 9:982128.

PMID: 36035413 PMC: 9403143. DOI: 10.3389/fmed.2022.982128.

References

Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A . Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009; 54(6):1012-24. DOI: 10.1053/j.ajkd.2009.07.020. View

Kerbert A, Verspaget H, Navarro A, Jalan R, Sola E, Benten D . Copeptin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival. Crit Care. 2017; 21(1):321. PMC: 5740749. DOI: 10.1186/s13054-017-1894-8. View

Mardini H, Smith F, Record C, Blamire A . Magnetic resonance quantification of water and metabolites in the brain of cirrhotics following induced hyperammonaemia. J Hepatol. 2010; 54(6):1154-60. DOI: 10.1016/j.jhep.2010.09.030. View

Bing C, Trayhurn P . New insights into adipose tissue atrophy in cancer cachexia. Proc Nutr Soc. 2009; 68(4):385-92. DOI: 10.1017/S0029665109990267. View

Hanai T, Shiraki M, Ohnishi S, Miyazaki T, Ideta T, Kochi T . Impact of serum glycosylated Wisteria floribunda agglutinin positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis. Hepatol Res. 2015; 45(11):1083-90. DOI: 10.1111/hepr.12473. View

Tseng T, Liu C, Su T, Yang W, Chen C, Yang H . Fibrosis-4 index predicts cirrhosis risk and liver-related mortality in 2075 patients with chronic HBV infection. Aliment Pharmacol Ther. 2018; 47(11):1480-1489. DOI: 10.1111/apt.14619. View

Gluud L, Dam G, Les I, Marchesini G, Borre M, Aagaard N . Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017; 5:CD001939. PMC: 6481897. DOI: 10.1002/14651858.CD001939.pub4. View

Ahluwalia V, Heuman D, Feldman G, Wade J, Thacker L, Gavis E . Correction of hyponatraemia improves cognition, quality of life, and brain oedema in cirrhosis. J Hepatol. 2014; 62(1):75-82. PMC: 4272614. DOI: 10.1016/j.jhep.2014.07.033. View

Batista Jr M, Olivan M, Alcantara P, Sandoval R, Peres S, Neves R . Adipose tissue-derived factors as potential biomarkers in cachectic cancer patients. Cytokine. 2012; 61(2):532-9. DOI: 10.1016/j.cyto.2012.10.023. View

10.

Koutsounas I, Kaltsa G, Siakavellas S, Bamias G . Markers of bacterial translocation in end-stage liver disease. World J Hepatol. 2015; 7(20):2264-73. PMC: 4568487. DOI: 10.4254/wjh.v7.i20.2264. View

11.

Ronald J, Wang Q, Choi S, Suhocki P, Hall M, Smith T . Albumin-bilirubin grade versus MELD score for predicting survival after transjugular intrahepatic portosystemic shunt (TIPS) creation. Diagn Interv Imaging. 2017; 99(3):163-168. DOI: 10.1016/j.diii.2017.10.008. View

12.

Kawaguchi T, Izumi N, Charlton M, Sata M . Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology. 2011; 54(3):1063-70. DOI: 10.1002/hep.24412. View

13.

Chen S, Wan Q, Wang T, Zhang K . Fluid Biomarkers for Predicting the Prognosis of Liver Cirrhosis. Biomed Res Int. 2020; 2020:7170457. PMC: 7114768. DOI: 10.1155/2020/7170457. View

14.

Ishikawa T, Imai M, Ko M, Sato H, Nozawa Y, Sano T . Evaluation of the branched-chain amino acid-to-tyrosine ratio prior to treatment as a prognostic predictor in patients with liver cirrhosis. Oncotarget. 2017; 8(45):79480-79490. PMC: 5668060. DOI: 10.18632/oncotarget.18447. View

15.

Cholongitas E, Calvaruso V, Senzolo M, Patch D, Shaw S, OBeirne J . RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit. J Gastroenterol Hepatol. 2009; 24(10):1639-47. DOI: 10.1111/j.1440-1746.2009.05908.x. View

16.

Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi F . Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018; 391(10138):2417-2429. DOI: 10.1016/S0140-6736(18)30840-7. View

17.

Hsu C, Lin H, Huang Y, Su C, Lee F, Huo T . Comparison of the model for end-stage liver disease (MELD), MELD-Na and MELDNa for outcome prediction in patients with acute decompensated hepatitis. Dig Liver Dis. 2009; 42(2):137-42. DOI: 10.1016/j.dld.2009.06.004. View

18.

Hametner S, Ferlitsch A, Ferlitsch M, Etschmaier A, Schofl R, Ziachehabi A . The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test. PLoS One. 2016; 11(2):e0149230. PMC: 4760704. DOI: 10.1371/journal.pone.0149230. View

19.

Nishikawa H, Enomoto H, Ishii A, Iwata Y, Miyamoto Y, Ishii N . Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis. J Cachexia Sarcopenia Muscle. 2017; 8(6):915-925. PMC: 5700437. DOI: 10.1002/jcsm.12212. View

20.

Verna E, Brown R, Farrand E, Pichardo E, Forster C, Sola-Del Valle D . Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci. 2012; 57(9):2362-70. PMC: 3979299. DOI: 10.1007/s10620-012-2180-x. View